Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 6Recruiting 2Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Salivary Gland Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 275pembrolizumab 267Carboplatin 190Cyclophosphamide 185Biopsy 178Cisplatin 164Gemcitabine 139Paclitaxel 137Bevacizumab 123fludarabine 122Nivolumab 117Radiotherapy 113Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 88Capecitabine 88Dexamethasone 85Drug Therapy 76Pemetrexed 75Rituximab 73durvalumab 71Leucovorin 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 67atezolizumab 64Doxorubicin 64Radiation 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × trastuzumab biosimilar HLX02 × 90 days × Clear all
NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

University of Washington

Phase 2 Recruiting
25 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05408845 2026-05-04

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NRG Oncology

Phase 2 Recruiting
146 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡